Projects per year
Personal profile
Research Strategic Pillar
Dr. Randall Urban, VP and Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the following badge(s):
Research interests
- Drug Discovery
Research Strategic Pillar Keywords
- Infectious/ Immunological Health
Fingerprint
Dive into the research topics where Thomas Geisbert is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Paramyxoviridae and Bunyavirales Vaccines and Antibodies Center (PABVAX)
Geisbert, T. (PI)
National Institute of Allergy and Infectious Diseases
7/30/24 → 6/30/27
Project: Research project
-
-
Broadly Protective Antibodies for the Treatment of Ebola Virus Disease
Geisbert, T. (PI)
5/12/23 → 4/30/25
Project: Research project
-
HTS for small molecule drug development for henipaviruses
Geisbert, T. (PI)
University of Illinois at Chicago
11/29/22 → 9/30/25
Project: Research project
-
MCDC2204-011: Development of Vaccines to Prevent Crimean Congo Hemorrhagic Fever Virus or Henipavirus Infections in Humans
Geisbert, T. (PI)
Advanced Technology International
11/21/22 → 12/31/27
Project: Research project
-
Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates
Woolsey, C., Cross, R. W., Prasad, A. N., Agans, K. N., Borisevich, V., Deer, D. J., Dobias, N. S., Fears, A. C., Harrison, M. B., Heinrich, M. L., Fenton, K., Garry, R. F., Branco, L. M. & Geisbert, T. W., Dec 2024, In: Emerging Microbes and Infections. 13, 1, p. 2301061 2301061.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus
Cross, R. W., Fenton, K. A., Woolsey, C., Prasad, A. N., Borisevich, V., Agans, K. N., Deer, D. J., Dobias, N. S., Fears, A. C., Heinrich, M. L., Geisbert, J. B., Garry, R. F., Branco, L. M. & Geisbert, T. W., Feb 20 2024, In: Cell Reports Medicine. 5, 2, 101392.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus
Cross, R., Woolsey, C., Chu, V. C., Babusis, D., Bannister, R., Vermillion, M. S., Geleziunas, R., Barrett, K. T., Bunyan, E., Nguyen, A. Q., Cihlar, T., Porter, D. P., Prasad, A., Deer, D. J., Borisevich, V., Agans, K. N., Martinez, J., Harrison, M. B., Dobias, N. S. & Fenton, K. A. & 2 others, , Mar 15 2024, In: Science. 383, 6688, p. eadk6176 eadk6176.Research output: Contribution to journal › Article › peer-review
Open Access6 Scopus citations -
Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates
Zeitlin, L., Cross, R. W., Courtney, W., Brandyn, R. W., Borisevich, V., Agans, K. N., Prasad, A., Deer, D. J., Stuart, L., McCavitt-Malvido, M., Kim, D. H., Pettitt, J., Crowe, J. E., Whaley, K. J., Veesler, D., Dimitrov, A., Abelson, D. M., Geisbert, T. W. & Broder, C. C., 2024, In: Science Translational Medicine. 16, 741, eadl2055.Research output: Contribution to journal › Article › peer-review
-
Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection
To, A., Wong, T. A. S., Ball, A. H., Lieberman, M. M., Yalley-Ogunro, J., Cabus, M., Nezami, S., Paz, F., Elyard, H. A., Borisevich, V., Agans, K. N., Deer, D. J., Woolsey, C., Cross, R. W., Geisbert, T. W., Donini, O. & Lehrer, A. T., Jan 25 2024, In: Vaccine. 42, 3, p. 598-607 10 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations